Back to Archived News
Cytori Receives Two Patent Allowances Related to Uses of the Celution System Output
Tuesday, October 07, 2008
San Diego, CA -- Cytori Therapeutics received two Notices of Allowance from the U.S. Patent & Trademark Office for patents, which cover methods related to the Celution System output. These patent allowances add specific commercial applications to U.S. Patent No. 7,390,484, issued in June 2008, which covers the Celution System technology that processes adipose-derived stem and regenerative cells at a patient's bedside. The new patent allowances will provide significant additional protection for wide-ranging formulations and applications of the Celution System output.
One patent allowance covers methods for cooling and cryopreserving (freezing) the Celution System output (i.e., adipose-derived stem and regenerative cells) relevant to the Company's cell banking platform. Currently, Cytori is manufacturing its Celution System in the United States to be sold as part its StemSource(R) business, which is a comprehensive cell banking product being offered in Europe, Asia and other parts of the world.
A second patent allowance covers methods to combine the Celution System output with additives such as scaffolds, matrices, or other agents to increase therapeutic effect, optimize or localize cell delivery, enhance specific cell properties or promote cell differentiation. The additives covered by the claims include, but are not limited to the following:
- An agent that promotes cell differentiation, including growth factors, cytokines, proteins, pharmaceuticals, among others;
- Demineralized bone, tissue, or tissue fragment;
- Biological or artificial scaffold; and
- Immunosuppressive compound, antibiotic, or antimicrobial agent.
Delivery of the stem and regenerative cells may be improved by combining the cells with a scaffold or matrix; for example, demineralized bone may be combined with the Celution output to support orthopedic repair. The Celution output may also be combined with drugs, proteins, genes, or other agents to enhance cell properties or to induce the cells to differentiate. For example, combining adipose-derived stem and regenerative cells with hyaluronic acid has been shown preclinically to regenerate damaged spinal disc.
The Company's intellectual property portfolio related to the devices, methods and uses of adipose-derived stem and regenerative cells includes eight U.S. and international patents and over 120 applications pending worldwide. Combined with Cytori's proprietary know-how, exclusive supply agreements, and instrumentation, greater barriers-to-entry are being created to offer what the Company believes is the only safe, high-quality and effective adipose tissue-derived stem and regenerative cell processing device.
Cytori's goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution 800 System is being introduced in Europe and Asia Pacific into the reconstructive surgery market while the Celution 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, statements regarding the private placement, the expected closing of the private placement, the number of additional shares that could be sold in connection with exercise of warrants issued in the private placement, a need for further financing, our plans for expanding commercialization of our Celution 800/CRS System and for global marketing efforts for our Celution System-based StemSource Cell Bank business, and other risks and uncertainties described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Back to Archived News